Clinical Trials Logo

Hidradenitis Suppurativa clinical trials

View clinical trials related to Hidradenitis Suppurativa.

Filter by:

NCT ID: NCT01468233 Completed - Clinical trials for Hidradenitis Suppurativa (HS)

Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa

PIONEER II
Start date: November 2011
Phase: Phase 3
Study type: Interventional

A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).

NCT ID: NCT01468207 Completed - Clinical trials for Hidradenitis Suppurativa (HS)

Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa

PIONEER I
Start date: November 2011
Phase: Phase 3
Study type: Interventional

A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).

NCT ID: NCT01352078 Completed - Clinical trials for Hidradenitis Suppurativa

Wound Etiology and Healing Study

WE-HEAL
Start date: May 2011
Phase:
Study type: Observational

The purpose of the WE-HEAL Study is to help researchers use human tissue samples and health records to study the reasons why some patients heal quickly and some have problems healing wounds. All patients seen with an open wound or hidradenitis suppurativa are invited to participate. Information from this research may help to understand how to prevent and treat certain diseases.

NCT ID: NCT01063270 Completed - Clinical trials for Hidradenitis Suppurativa

Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa

Start date: February 2010
Phase: N/A
Study type: Interventional

The purpose of this research study is to further evaluate the efficacy of two treatment regimens for the treatment of hidradenitis suppurativa. This is a randomized controlled study. Patients will be randomly assigned to an arm of the study.

NCT ID: NCT00949546 Completed - Clinical trials for Hidradenitis Suppurativa

Treatment of Hidradenitis Suppurativa Using Etanercept

Start date: April 2005
Phase: N/A
Study type: Observational

Therapy with etanercept, a TNF inhibitor will reverse the inflammation, symptoms and quality of life and allow healing of HS.

NCT ID: NCT00918255 Completed - Clinical trials for Hidradenitis Suppurativa

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Start date: April 2009
Phase: Phase 2
Study type: Interventional

This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.

NCT ID: NCT00827996 Completed - Clinical trials for Hidradenitis Suppurativa

To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa

HIDRI2007
Start date: February 2007
Phase: Phase 2
Study type: Interventional

The trial is a 12-week phase 2 study. Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12 in subjects with moderate to severe hidradenitis suppurativa.

NCT ID: NCT00795574 Completed - Clinical trials for Hidradenitis Suppurativa

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

HS2006
Start date: June 2005
Phase: Phase 2
Study type: Interventional

A study to assess the safety and efficacy of the IV drug infliximab for the treatment of hidradenitis suppurativa

NCT ID: NCT00722800 Terminated - Clinical trials for Hidradenitis Suppurativa

A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if taking a birth control pill, YAZ, is safe and effective for treating hidradenitis suppurativa. Hidradenitis suppurativa (HS) is a chronic (long lasting) skin disorder that mostly affects the armpits and groin area. It appears as blackheads and one or more red, tender bumps that may enlarge, break open, and drain pus. Scarring may result after several attacks of the disease. The exact cause of HS isn't known. However, it is believed that the plugging of hair follicles and bacterial infection that occur in acne also occur in HS. Many of the medications used for treating acne are also used for HS. However, none of the medications are consistently effective. YAZ is a combination birth control pill. Nearly all birth control pills are made up of a combination of estrogen and progestin hormones. YAZ contains ethinyl estradiol (an estrogen) and drospirenone (a progestin). People who develop acne have sebaceous glands that are over-stimulated by male sex hormones (androgens). Sebaceous glands secrete an oily substance into a hair follicle to lubricate hair or skin. The progestin in YAZ actually blocks the male sex hormones (androgens) that cause acne. Hormones seem to play a role in HS as the condition occurs after puberty. It affects more women than men and HS often gets worse around the time a women has her menstrual period. YAZ has been approved by the U.S. Food and Drug Administration (FDA) to treat moderate acne in women who desire an oral contraceptive for birth control. This study uses a placebo. A placebo looks like the study drug but contains no active drug. We use placebos in research studies to learn if the effects seen in research subjects are truly from the study drug or from other reasons.

NCT ID: NCT00494351 Completed - Clinical trials for Hidradenitis Suppurativa

Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa

Start date: June 2007
Phase: N/A
Study type: Interventional

- Determination of the short and long term efficacy of NdYag laser for treatment of Hidradenitis suppurativa, which is an inflamed, deeper follicular disorders. - Determination of patient tolerance of discomfort associated with NdYag laser treatment for Hidradenitis suppurativa. - Determination of the impact of this condition on quality of life and if there is any impact of therapy in the dermatology quality of life index. - Evaluate the histopathologic changes of YAG therapy on affected skin Second phase of study: - Prospective, controlled clinical and histologic study of patients with Hurley Stage II HS disease. - 19 patients of skin types II to VI with Hurley Stage II hidradenitis suppurativa lesions of the axilla and groin. This is a different set of patients than those treated in the first phase of the study above. This study primarily focuses on and further characterizes the histologic changes after laser treatment.